REFERENCES
- Fabbri G, Petraglia F, Segre A, et al. Reduced spinal bone density in young women with amenorrhea. Eur J Obstet Gynecol Reprod Biol 1991;41:117–22.
- Davies MC, Hall ML, Jacobs HS. Bone mineral loss in young women with amenorrhea. Br Med J 1990;301: 790–3.
- Drinkwater BL, Brummer B, Chesnut CH III. Menstrual history as a determinant of current bone density in young athletes. JAMA 1990;263:545–8.
- Nappi C, Bifulco G, Tommaselli GA, et al. Hormonal contraception and bone metabolism: A systematic review. Contraception 2012;86:606–21.
- Berenson AB, Radecki CM, Grady JJ, et al. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol 2001;98: 576–82.
- Nappi C, Di Spiezio Sardo A, Acunzo G, et al. Effects of a low-dose and ultra-low-dose combined oral contraceptive use on bone turnover and bone mineral density in young fertile women: A prospective controlled randomized study. Contraception 2003;67:355–9.
- Nappi C, Di Spiezio Sardo A, Greco E, et al. Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density. Obstet Gynecol 2005; 105:53–60.
- Endrikat J, Mih E, Dusterberg B, et al. A 3-year double-blind, randomized, controlled study on the influence of two oral contraceptives containing either 20 μg or 30 μg ethinylestradiol in combination with levonorgestrel on bone mineral density. Contraception 2004;69: 179–87.
- Gargano V, Massaro M, Morra I, et al. Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: A prospective controlled randomized study. Contraception 2008;78:10–5.
- Hartard M, Kleinmond C, Luppa P, et al. Comparison of the skeletal effects of the progestogens desogestrel and levonorgestrel in oral contraceptive preparations in young women: Controlled, open, partly randomized investigation over 13 cycles. Contraception 2006;74: 367–75.
- Paoletti AM, Orru M, Floris S, et al. Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women. Contraception 2000; 61:259–63.
- Düsterberg B, Nishino Y. Pharmacokinetic and pharmacological features of oestradiol valerate. Maturitas 1982; 4:315–24.
- Ruan X, Seeger H, Mueck AO. The pharmacology of dienogest. Maturitas 2012;71:337–44.
- Oettel M, Graser T, Hoffman H. Why dienogest as a progestogenic component of postmenopausal nonandrogenic hormone replacement therapy. Drugs Today 2001;37:3–15.
- Guida M, Bifulco G, Di Spiezio Sardo A, et al. Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill. Int J Womens Health 2010;2:279–90.
- Block G, Hartman AM, Dresser CM, et al. A data-based approach to diet questionnaire design and testing. Am J Epidemiol 1986;124:453–69.
- Robin SP. Biochemical markers of bone metabolism. CPD Bulletin Clin Biochem 1999;1:116–21.
- Delmas PD. Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease. Endocrinol Metab Clin North Am 1990;19:1–18.
- The ESHRE Capri Workshop Group. Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update 2005;11:513–25.
- Warholm L, Petersen KR, Ravn P. Combined oral contraceptives’ influence on weight, body composition, height, and bone mineral density in girls younger than 18 years: A systematic review. Eur J Contracept Reprod Health Care 2012;17:245–53.